AI Article Synopsis
- An amendment to the paper has been released.
- The amendment can be accessed through a link provided at the top of the original paper.
- This update may include important changes or additional information.
Article Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584569 | PMC |
| http://dx.doi.org/10.1038/s41419-020-02933-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction to: ERK/HIF-1α/VEGF pathway: a molecular target of ELABELA (ELA) peptide for attenuating cardiac ischemia-reperfusion injury in rats by promoting angiogenesis.
Mol Biol Rep
May 2023
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Correction: ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway.
Cell Death Dis
October 2020
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Article Synopsis
- An amendment to the paper has been released.
- The amendment can be accessed through a link provided at the top of the original paper.
- This update may include important changes or additional information.
Evaluation of elabela, apelin and nitric oxide findings in maternal blood of normal pregnant women, pregnant women with pre-eclampsia, severe pre-eclampsia and umbilical arteries and venules of newborns.
J Obstet Gynaecol
October 2019
Department of Medical Biochemistry and Clinical Biochemistry (Firat Hormones Research Group), Medical School, Firat University, Elazig , Turkey.
Pre-eclampsia is multisystem metabolic diseases, commonly accompanied by hypertension and proteinuria, which are among the important causes of maternal and perinatal mortality and morbidity worldwide. In a pre-eclampsia animal model study in the last year, Elabela (ELA) infusion was reported to correct hypertension and proteinuria and to normalise the birth weights of the offspring. Therefore, our main goal in this human study is to compare ELA, apelin (APLN) and nitric oxide (NO) levels in the maternal blood of pregnant women with pre-eclampsia and severe pre-eclampsia and in their newborns' venous-arterial cord blood with maternal blood of healthy pregnant women and their newborns' venous-arterial cord blood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!